![CinDome](https://parsers.vc/logo/fd89255e-a07a-4c70-bb50-303ba9fcd33a-3.webp)
CinDome Pharma, a CinRx portfolio company, is advancing deudomperidone (CIN-102) for the treatment of chronic gastroparesis.
Total raised: $40M
Funding Rounds 1
Date | Series | Amount | Investors |
16.05.2024 | Series B | $40M | - |
Mentions in press and media 2
Date | Title | Description |
16.05.2024 | CinDome Pharma Raises $40M in Series B Extension | CinDome Pharma, a Cincinnati, OH-based company dedicated to advancing a safe, chronic therapy for gastroparesis, raised $40M in Series B extension funding. The round, which brought the total amount to $59M, included participation from Perce... |
- | CinDome Pharma | “CinDome Pharma, a CinRx portfolio company, is advancing deudomperidone (CIN-102) for the treatment of chronic gastroparesis.” |